CYP2C8*3 increases risk of neuropathy in breast cancer patients treated with paclitaxel.

Hertz, D L

CYP2C8*3 increases risk of neuropathy in breast cancer patients treated with paclitaxel. [electronic resource] - Annals of oncology : official journal of the European Society for Medical Oncology Jun 2013 - 1472-8 p. digital

Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

1569-8041

10.1093/annonc/mdt018 doi


Adult
Black or African American--genetics
Aged
Aged, 80 and over
Antineoplastic Agents, Phytogenic--therapeutic use
Aryl Hydrocarbon Hydroxylases--genetics
Breast Neoplasms--drug therapy
Cohort Studies
Cytochrome P-450 CYP2C8
Female
Genetic Variation--genetics
Humans
Middle Aged
Paclitaxel--adverse effects
Paraneoplastic Polyneuropathy--chemically induced
Risk Factors
Treatment Outcome
White People--genetics
Young Adult